In 2004, Markus Depfenhart completed his medical studies and received his doctorate from the JWG University in Frankfurt am Main in 2005. He later underwent further studies in other subjects and so he now also holds a LL.M. in economic law and a PhD in business and economics. Among others he developed an algorithm for legal patent circumvention.
After numerous theoretical and practical training courses, he qualified as board certified emergency physician in 2008 and worked as an emergency physician in Hamburg, but also in crisis regions such as the Balkans and Afghanistan. Since 2014, he has been a board certified specialist in plastic and aesthetic surgery. Due to numerous stays abroad, for example in Greece, South Africa and the USA, Markus Depfenhart can demonstrate international experience in various specialties and is also constantly educating himself in this country. He is a also an expert for skin and skincare realetd topics and of his major focusses is now peptide and protein design. In 2018 Markus Depfenhart has been appointed as professor for aesthetic and regenerative medicine at the Venlo University/ NL. Since 2020 he is also lecturing at the FOM University of Applied Science in Hamburg/ Germany. He also works as a consultant for the industry and has a seat on the advisory board of various national and international companies. He is currently a member of the board of Lavenir Bioscience AG (Hamburg) and the Optiphi AG (Switzerland). Markus Depfenhart holds more than 30 patents and patent applications in different fields.
- Reviewed publications:
Granted patents and patent applications:
- Depfenhart, M., Müller, J., Trieu, H.-K., & Spanic, M. (2017). DE Patent No. 10 2017 106 310 B4. München: Deutsches Patent- und Markenamt .
- Depfenhart, M., & Müller, J. (2014). DE Patent No. 10 2014 017 197 B4. München: Deutsches Patent- und Markenamt .
- Depfenhart, M., & Müller, J. (2011). DE Patent No. 10 2011 052 002 B4. München: Deutsches Patent- und Markenamt .
- Depfenhart, M. (2013). EP Patent No. 2 837 957 B1. München: European patent office.
- Depfenhart, M. (2012). EP Patent No. 2 745 820 B1. München: European patent office.
- Depfenhart, M. (2012). EP Patent No. 2 745 819 B1. München: European patent office.
- Depfenhart, M., & Müller, J. (2012). EP Patent No. 2 548 617 B1. München: European patent office.
- Depfenhart, M. (2013). U.S. Patent No. 10,258,506 B2. Washington, DC: U.S. Patent and Trademark Office.
- Depfenhart, M. (2013). U.S. Patent No. 10,098,782 B2. Washington, DC: U.S. Patent and Trademark Office.
- Depfenhart, M., & Müller, J. (2012). U.S. Patent No. 9,486,284 B2. Washington, DC: U.S. Patent and Trademark Office.
- Depfenhart, M. (2014). U.S. Patent No. 9,063,282 B2. Washington, DC: U.S. Patent and Trademark Office.
- Depfenhart, M., & Van der Wat, L. (2018). WO International Patent Publication No. Patent No. 2020/016775 A1. Geneva, Switzerland: World Intellectual Property Organization.
- Depfenhart, M., Müller, J., Trieu, H.-K., & Spanic, M. (2018). WO International Patent Publication No. 2018/172015 A1. Geneva, Switzerland: World Intellectual Property Organization.
- Depfenhart, M., Müller, J. (2015). WO International Patent Publication No. 2016/079717 A1. Geneva, Switzerland: World Intellectual Property Organization.
- Depfenhart, M. (2017). WO International Patent Publication No. 2018/211311 A1. Geneva, Switzerland: World Intellectual Property Organization.
- Depfenhart, M., & Müller, J. (2015). U.S. Pub. No. 2017/0348543 A1. Washington, DC: U.S. Patent and Trademark Office.
- Depfenhart, M. (2014). U.S. Pub. No. 2015/0049391 A1. Washington, DC: U.S. Patent and Trademark Office.
- Depfenhart, M. (2013). U.S. Pub. No. 2014/70171927 A1. Washington, DC: U.S. Patent and Trademark Office.
- Depfenhart, M. (2013). U.S. Pub. No. 2014/0171926 A1. Washington, DC: U.S. Patent and Trademark Office.
- Depfenhart, M., & Müller, J. (2012). U.S. Pub. No. 2013/0023966A1. Washington, DC: U.S. Patent and Trademark Office.
- Depfenhart, M., & Müller, J. (2015). AU Application No. 2015348949 A1. Canberra: Australian Patent Office.
- Depfenhart, M., & Müller, J. (2014). AU Application No. 2014213488 A1. Canberra: Australian Patent Office.
- Depfenhart, M., & Müller, J. (2015). CN Application No. 107249686A. Peking: China National Intellectual Property Administration.
- Depfenhart, M. (2016). DE Offenlegungsschrift No. 10 2016 006 083 A1. München: Deutsches Patent- und Markenamt .
- Depfenhart, M., & Müller, J. (2014). DE Offenlegungsschrift No. 10 2014 017 197 A1. München: Deutsches Patent- und Markenamt.
- Depfenhart, M., & Müller, J. (2011). DE Offenlegungsschrift No. 10 2011 052 002 A1. München: Deutsches Patent- und Markenamt.
- Depfenhart, M., & Müller, J. (2012). EP Patentanmeldung No. 3 22 1003 A1. München: European patent office.
- Depfenhart, M., & Müller, J. (2012). EP Patentanmeldung No. 2 548 617 A1. München: European patent office.
- Depfenhart, M. (2013). EP Patentanmeldung No. 2 745 819 A1. München: European patent office.
- Depfenhart, M. (2013). EP Patentanmeldung No. 2 745 820 A1. München: European patent office.
- Depfenhart, M. (2013). EP Patentanmeldung No. 2 837 957 A1. München: European patent office.
- Depfenhart, M. (2018). KR Patentanmeldung No. 10 2017 087 490 A. Seoul: Korean Intellectual Property Office.
Further Peer- reviewed publications
- Wetterling, T., Weber, B., Depfenhart, M., Schneider, B., Junghanns, K. (2006). Development of a rating scale to predict the severity of alcohol withdrawal syndrome, Alcohol and Alcoholism, Volume 41, Issue 6, 611- 615.
- Depfenhart, M. et al. (2020). A SARS-CoV-2 Prophylactic and Treatment ; A Counter Argument Against The Sole Use of Chloroquine. Am. J. Biomed. Sci. & Res. 8, 248–251.
- Depfenhart, M., de Villiers, D., Lemperle, G. et al. (2020). Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?. Intern Emerg Med. https://doi.org/10.1007/s11739-020-02383-3.
- Oetama, S., Tandayu, K., Depfenhart, M., Meyer,M. (2020). Asymptomatic and Minimally Symptomatic COVID-19 in Medical Frontliners: A Case Series from National Cardiovascular Centre Harapan Kita Indonesia. Int J Med Rev Case Rep, 4(9): 43-48.
- Marianno Franzini, Luigi Valdenassi, Giovanni Ricevuti, Salvatore Chirumbolo, Markus Depfenhart, Dario Bertossi, Umberto Tirelli. Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19 (2020). Preliminary evidence reported,International Immunopharmacology,Volume 88, 06879,ISSN 1567-5769.
- Shahid Nadeem, M., Ali, A., Al-Ghamdi, M. A., Depfenhart, M., Azam Khan, J., Zamzami, M. A., Nazia Murtaza, B., Kazmi, I., & Ur Rehman, M. (2020). COVID-19: Prospective Challenges and Potential Vaccines. Alternative therapies in health and medicine, 26(S2), 72–78.
2. Reviewed conference proceedings
- Depfenhart, M., Elsner, A., Meyer, H. (2018). Modern Patent Management an area of conflict between legal protection and economic significance, ICSB World Conference Proceedings 2018. Michigan: ProQuest Pub.
Monographs
- Depfenhart, M. (2006). Schlafqualität als Prädiktor für die Schwere des Entzugs bei Alkoholikern (Dissertation/ Doctorate Thesis).
- Depfenhart, M. (2018). Schlafqualität Als Prädiktor für die Schwere des Entzugs bei Alkoholikern. North Charleston: Createspace Independent Pub.
- Depfenhart, M. (2017). Modernes Patentmanagement zwischen Rechtsschutz und ökonomischer Bedeutsamkeit (Master Thesis, Law).
- Depfenhart, M. (2020). Modern patent management as an area of conflict between legal protection and economic significance: Design of a simple and effective patent circumvention algorithm (Doctorate/ Ph.D. Thesis, Management and Economics).
Other publications
Depfenhart, M. (2019): Tattoo Update. Men's Health Magazine, October 2019, 29-32.
Depfenhart, M. (2019): From Lifespan to Healthspan. Longevity Magazine, Annual issue 2018, December 2018, 21-22.
Depfenhart, M. (2019): The Renaissance of Cell Therapies. Longevity Magazine, Annual issue 2019, August 2019, 9-10.
Depfenhart, M. et al. (2020): „Drug Repurposing“ – die aktuell schärfste Waffe gegen COVID-19, Plastische Chirurgie, 02/2020, 93-95.
Depfenhart, M. (2019): The case for drug repurposing. Longevity Magazine, Holiday edition 2020, October 2020, 26.